Incyte (INCY) stock

Cancer drugs , market cap $24B

Cancer drugs

Market cap $24B

$120.04

-0.29%

As of Monday's close · Live for Pro members at the open

Quality Score

Above Average

In its industry

#26of 291

Biotech

Checks firing

2of 14

Transition

From 52-week high

-9.5%

Above the 200-day

INCY's Quality Score fell 2 points on Mon, Nov 2, to 12. Trading went back to normal after a busy day (2 chart checks stopped).

Follow INCY's trial news. Pro members can get an alert when Incyte files news, and see its trials, share raises, and its CEO's filings.

Get an alert when INCY files news on its trialsSee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

NextQ4 2026“A regulatory decision from the EC is anticipated in the fourth quarter of 2026.”Regulatory decision · SEC filing · Oct 29

What INCY filed on Oct 29

Down 0.1% on Oct 29 while the S&P 500 fell 0.4%.

Its Oct 29 results: earnings per share swung to a loss of $3.86, from a profit of $2.11 a year before. It fell 0.1% on Oct 29.

Sources: Price history, Oct 29, 2026; Company release, Oct 29, 2026

1 more reason, free with an account →The timeline and its peers, for Pro members.

Key facts on INCY

Key facts on INCY
The chart	Above every average
Latest filing	8-K, Oct 29 Reported its quarterly results

1 more reason behind INCY's 12, free with an account →3 more reasons behind INCY's 12, for Pro members.

INCY in the news

Fri Oct 30Oppenheimer upgraded INCY to Outperform Investing.com Canada and 1 more INCY closed +3.1% that day.

What's next

Expected to report Tue Feb 9, before the open

After its last 4 reports it closed +0.8% on average, higher 2 of 4 times.

INCY catalysts

Coming up

21 more coming up and 32 past catalysts since 2018, with sizes and sources, for Pro members.Get in free →

What's next for INCY

Next step the company has named

Q4 2026“A regulatory decision from the EC is anticipated in the fourth quarter of 2026.”Regulatory decision · SEC filing · Oct 29

What it means: a regulator’s decision on an application to sell the drug.

A trial underway: STOP-HS LTEPhase 3 · Active · 617 people · main data estimated Dec 26, 2026 · NCT06212999

53 more trials, 4 with data due this year, 11 more milestones and 30 filings, for Pro members.

Dilution on the horizon

No shelf registration or at-the-market program on file in the last three years.

For Pro members: the amounts, and the share count against a year ago.

Insiders

An officer, Pablo J. Cagnoni, sold 2,642 shares on Oct 15, under a planned sale. 18 more insider trades this year.

From Form 4: open-market buys and sales only.

Get an alert when William Meury buys or sells

For Pro members: every trade, and William Meury’s 6 filings and quotes.

Get an alert when INCY files news on its trialsSee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 20 daysFDA decisionIn 20 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $385MDeramiocelFDA decision due (PDUFA)
In 20 daysFDA decisionIn 20 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $1.0BMolgramostimFDA decision due (PDUFA)
In 50 daysFDA decisionIn 50 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.9BLorundrostatFDA decision due (PDUFA)

11 more FDA dates and 102 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 143 dates, ranked →

Why INCY scores 12

Above Averagefor quality, not price, 2 of 14 chart checks firingWhat the Quality Score means

+3Long-term trend above a rising 200-⁠day average, near its 52-⁠week high
+3News guidance raised, earnings beat, analyst upgrade, earnings release

Chart checks adds
Size adds
Profit addsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
Growth addsSales and margins against a year earlier: up to +3 for fast growth and widening margins, down to -2 when both shrink.

No effect today: Run-up, Dilution, Volatility, Cash flow, and Persistence.

What every line is worth, and the reason behind it, on INCY and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 9:36 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-⁠scored stocks returned 2.2x the average stock over the next month. How we tested it

Alert me when INCY's Quality Score turns up

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

Here is what Pro members see.

The same page for Pro members, on AMD
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on INCY and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

INCY has 2 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on INCY, and all 14 on every stock.Get in free →

INCY RSI today: 56.7, below its 50-day, above its 200-day

Not scored

Not in the Quality Score: over 20 years of tests, 2006 to 2026, they added no edge.

RSI 1456.7
Above 50, below 70.
MACD (12, 26, 9)Above signal
Crossed above its signal line 9 sessions ago.
50-day average$120.33
The price is 0.2% below it.
200-day average$108.13
The price is 11.0% above it.
50/200 crossGolden cross
The 50-day crossed above the 200-day on Jul 30, 2025.
ADX 1418.8
Under 25, with +DI below -DI.
Support$119.97
Swing low from Sep 15, 0.1% below the price.
Resistance$128.72
Swing high from Sep 18, 7.2% above the price.
52-week high$132.60
From Jul 28, 10.5% above the price.
52-week low$89.25
From Mar 24, 25.6% below the price.
Chart patternNone
No triangle, channel, or wedge in the last year.
Bollinger Bands (20, 2)Inside
The bands run from $108.76 to $120.20.
Volume0.9x
Against its 20-day average, for the time of day.

The deep dive on INCY

What it does and how it makes money7 findingsRoyalties made up 12% of its revenue in fiscal 2025 ($637M of $5.14B), against 14% in fiscal 2024; product sales 85%.SEC filing · Feb 10, 2026"Ruxolitinib phosphate salt patents are issued in the US, the EU, and Japan with anticipated expiration dates of late-2028 in the US and mid-2028 in the EU and Japan." (10-K for fiscal 2025)SEC filing · Feb 10, 2026
Where it stands1 findingFor Pro members1 finding on where INCY stands: its cash, debt, and share count, for Pro members
What changed in its filings8 findings"In response, we filed patent infringement actions against each of the Generic JAKAFI Manufacturers (including with respect to both the ANDA and 505(b)(2) NDA for Apotex, Inc.) in the U.S. District Court for the District of New Jersey asserting certain FDA Orange-Book-listed patents for JAKAFI." (10-Q for the quarter to Mar 31, 2026)SEC filing · Apr 28, 2026A new heading in its "Risk Factors" this year: "Changes in government pricing policies, including the enactment of “most favored nation” pricing legislation, could adversely affect our business." (10-K for fiscal 2025; not in fiscal 2024's)SEC filing · Feb 10, 2026, against the one of Feb 10, 2025One customer made up 21% of its revenue in fiscal 2025, up from 19% in fiscal 2024.SEC filing · Feb 10, 2026
Who holds and trades it2 findingsFor Pro members2 findings on who holds and trades INCY, for Pro members

13 more findings on INCY, each with its source, for Pro membersGet in free →

How INCY ranks in Biotech

INCY is #26 of 291 by Quality Score.

How INCY ranks in Biotech
1	KNSAKiniksa Pharmaceuticals International	6/14	21
2	TGTXTG Therapeutics	8/14	19
3	AMGNAmgen	5/14	19
	IMVTImmunovant		Open for its score
	INBXInhibrx Biosciences		Open for its score
	INDPIndaptus Therapeutics		Open for its score
	INDVIndivior Pharmaceuticals		Open for its score
26	INCYIncyte	2/14	12

When does INCY report earnings, and what happens after?

Expected to report Tue Feb 9, before the open (in 99 days). Expected.

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What INCY reported on Oct 29, 2026

The quarter

Sales of $1.6B, 14% more than a year ago; a loss of $3.86 a share, from a profit of $2.11.

“Total revenue was $1.56 billion, an increase of 14% compared to the third quarter of 2025, primarily driven by an increase in total net sales across marketed products.”

The quarter that ended Sep 30, from the company's press release

The press release The filing on EDGAR

Where the sales came from

INCY's results filing gives no sales by line in a table we read.

The outlook

The outlook the company gave, by period
Measure	Figure
Full year 2026
Opzelura net sales	$1.10B to $1.12Braised

Figures as filed (SEC filing, Oct 29)

2 more outlook lines, for Pro members.

In the company's words

“Total net sales were $1.32 billion, an increase of 14% compared to the third quarter of 2025, driven by increased demand across marketed products.”

From its results filing (SEC filing · Oct 29)

The numbers

Market value: $24B; today

No analyst estimates on Breakaway: every figure here is filed.

The whole report on INCY: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.Get in free →

+2.1%+9.3%-0.1%

Apr 28Jul 28Oct 29

Reported	When	Gap	Reaction	5 sessions
Oct 29, 2026Before open	Before open	-4.5%	-0.1%	open
Jul 28, 2026Before open	Before open	+0.1%	+9.3%	-0.4%
Apr 28, 2026Before open	Before open	-1.0%	+2.1%	+1.5%

INCY closed higher after 2 of its last 4 reports.

All 4 reports, and INCY's Quality Score going into each

INCY sales and profit by year

Sales and profit by year

Sales grew every year from 2018 to 2025, to $5.1B. It made a profit in seven of the eight years.

INCY share count over time

Shares: 2.9% more than a year ago (to Mar 31).

Shares of INCY outstanding, as filed
Shares outstanding	As of
199.8M	Apr 21, 2026
199M	Feb 3, 2026
196.3M	Oct 21, 2025
195.3M	Jul 22, 2025

Offerings, shelves, and splits of INCY, from its filings
From its filings	Filed
Registered shares for a later sale (S-3ASR)	Feb 10, 2025

INCY's officers and directors

Officers and directors with a Form 4 in the last 12 months.

William MeuryChief Executive Officer
Suketu UpadhyayEVP & Chief Financial Officer
Pablo J. CagnoniPresident, Global Head of R&D · 9 trades
Steven H. SteinCMO & Head of Late-Stage Dev. · 6 trades
Thomas TrayPrincipal Accounting Officer · 6 trades
Patrick A. MayesEVP & Chief Scientific Officer · 5 trades
Michael James MorrisseyEVP, Head of Tech. Operations · 2 trades
Mohamed Khairie IssaEVP, Head of U.S. Commercial · 2 trades

13 more officers and directors file at INCY. Each page above names the rest.

See insider trades by person

Which ETFs hold INCY?

In ETFs: INCY is under 0.1% of IVV, under 0.1% of SPY, and under 0.1% of VOO, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026 (SPY's as filed by IVV).

About Incyte

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.

2,844 employeesWilmington, DEincyte.com

What Incyte says it competes with

“Our drug discovery, development and commercialization activities face, and will continue to face, intense competition from organizations such as pharmaceutical and biotechnology companies, as well as academic and research institutions and government agencies.”

From its annual report, SEC filing · Feb 10, 2026

2 more sentences, what it says it does, and its sales by region, for Pro membersGet in free →

INCY's score card

Incyte (INCY): Quality Score 12, Above Average, #26 of 291 in Biotech, with its price, on Breakaway — The picture a link to this page shows when it is shared.

Pro members see every line of every stock's score.

What would move INCY's score: 5 things
3 more filings explained, a plain line each
Real-⁠time prices, no delay

See INCY's 14 chart checks

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

Straight Answers

As of Nov 2, 2026: INCY's Quality Score is 12 (Above Average), #26 of 291 in Biotech.

Is INCY a good stock to buy? What its Quality Score says

INCY scores 12 today, which Breakaway calls Above Average. It is #26 of 291 in Biotech by Quality Score, with 2 of 14 chart checks firing. Down 0.1% on Oct 29 while the S&P 500 fell 0.4%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is INCY's Quality Score?

INCY scores 12 today, which Breakaway calls Above Average (11 to 14). That is #26 of 291 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind INCY's 12.

When does INCY report earnings?

Expected to report Tue Feb 9, before the open, a date Breakaway expects from the company's usual timing; the company has not confirmed it. INCY closed higher after 2 of its last 4 reports. Past behavior, not a forecast.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.